Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)
Dianthus Therapeutics' (DNTH) quarterly Non-Current Deffered Revenue came in at $5.8 million in Q4 2025, up 202.41% year-on-year from $1.9 million in Q4 2024, and down 4.91% quarter-over-quarter from $6.1 million in Q3 2025.
Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- On a quarterly basis, Non-Current Deffered Revenue rose 202.41% year-over-year to $5.8 million in Q4 2025; TTM through Dec 2025 was $5.8 million, a 202.41% increase from a year earlier, with the FY2025 full-year figure at $5.8 million, up 202.41% from the prior year.
- Non-Current Deffered Revenue declined to $5.8 million in Q4 2025 per DNTH's latest filing, from $6.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $6.4 million in Q2 2021 and bottomed at $640000.0 in Q3 2024.
- The 5-year median for Non-Current Deffered Revenue is $1.9 million (2025), against an average of $3.2 million.
- Across the five-year window, Non-Current Deffered Revenue tumbled 87.64% in 2022 and soared 848.12% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $6.4 million in 2021, then tumbled by 87.64% to $791000.0 in 2022, then retreated by 6.95% to $736000.0 in 2023, then jumped by 159.24% to $1.9 million in 2024, then surged by 202.41% to $5.8 million in 2025.
- Per Business Quant, the three latest DNTH Non-Current Deffered Revenue figures stand at $5.8 million (Q4 2025), $6.1 million (Q3 2025), and $1.8 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.92 Bn | 3.51 Bn | - | 5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 6.07 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 640,000.00 |
| Jun 30, 2024 | 682,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 736,000.00 |
| Sep 30, 2023 | 745,000.00 |
| Dec 31, 2022 | 791,000.00 |
| Dec 31, 2021 | 6.40 Mn |
| Sep 30, 2021 | 6.40 Mn |
| Jun 30, 2021 | 6.40 Mn |
| Mar 31, 2021 | 6.36 Mn |
| Dec 31, 2020 | 6.28 Mn |
| Sep 30, 2020 | 6.21 Mn |
| Jun 30, 2020 | 6.44 Mn |
| Mar 31, 2020 | 6.34 Mn |
| Dec 31, 2019 | 6.21 Mn |